Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to Jennifer R Diamond

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Diamond, Jennifer

One or more keywords matched the following items that are connected to Diamond, Jennifer

Item Type	Name
Academic Article	BRCA in breast cancer: from risk assessment to therapeutic prediction.
Academic Article	Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
Academic Article	Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
Academic Article	Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
Academic Article	Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models.
Concept	Antineoplastic Agents
Academic Article	From bench to bedside: lessons learned in translating preclinical studies in cancer drug development.
Academic Article	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
Academic Article	Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.
Academic Article	A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
Academic Article	Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.
Academic Article	Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
Academic Article	Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Academic Article	Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly ? 2 every-3-week schedule.
Academic Article	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Academic Article	A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
Academic Article	Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.
Academic Article	A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
Academic Article	A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
Academic Article	Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Academic Article	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Concept	Antineoplastic Agents, Immunological
Academic Article	Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4.
Academic Article	Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Academic Article	First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits ?-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.
Academic Article	Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials.
Academic Article	Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation.
Academic Article	Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.

Search Criteria

Antineoplastic Agents